Clofarabine concentrate for solution for infusion, 1 mg/ml (20ml)

Relapsed or refractory acute lymphoblastic leukemia

Ivozall® is a concentrate of clofarabine for the treatment of relapsed or refractory acute lymphoblastic leukemia. Acute lymphoblastic leukemia is a type of cancer that affects white blood cells. It progresses quickly and aggressively and requires immediate treatment.

Although rare, acute lymphoblastic leukemia is the most common type of blood cancer that affects children. About 85% of cases happen in those younger than 15 (mostly between the ages of 0 and 5).

Pharmaceutical form

Ivozall® is concentrate for solution for infusion of clofarabine, 1 mg/ml, 20ml.


Ivozall® is approved for the treatment of acute lymphoblastic leukemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis (1)


France  :
ORPHELIA Pharma exploite le médicament :
IVOZALL 1mg/ml, solution à diluer pour perfusion (clofarabine)

Pour toute déclaration liée à un effet indésirable de nos médicaments, veuillez contacter le service Pharmacovigilance à l’adresse suivante :

Pour toutes questions sur nos médicaments, veuillez contacter le service Information Médicale à l’adresse suivante :

Pour toute réclamation qualité, veuillez contacter le service Qualité à l’adresse suivante : pqc@orphelia-pharma.eu

Contact téléphonique :

Consulter la base de données publique des médicaments

Spain :
BCN Farma, Barcelona, Spain

Entafarma, Širvintos, Lithuania